Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical Companies has initiated shipment of modafinil tablets, a generic version of Teva's Provigil brand.
Subscribe to our email newsletter
Par’s initial shipments will comprise generically-labeled presentations of the Provigil product.
Modafinil, a wakefulness-prompting agent for oral administration, indicated to improve wakefulness in adult patients with excessive sleepiness related to narcolepsy, obstructive sleep apnea (OSA), and shift work disorder.
The product is indicated as an adjunct to standard treatment(s) for the underlying obstruction, in OSA.
Par acquired the US marketing rights to modafinil from Teva in connection with Teva’s acquisition of Cephalon in 2011.